Celebrating the Annals of Surgical Oncology’s 25-Year Anniversary: One of the Most Cited Surgical Journals in the World

Balch, Charles M.; Roh, Mark S.; McMasters, Kelly M.; Whippen, Deborah

doi:10.1245/s10434-017-6261-0

Cited by 2 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, tumor detection methods during surgery rely on visual palpation, intraoperative ultrasound, and frozen section analysis. 9 Although useful, these methods are experience dependent, time-consuming, and constrained by sample errors. 10 Therefore, an intraoperative imaging method as an adjunct to them can be both helpful to surgeons in recognizing breast tumors during resection and to pathologists in locating suspicious lesions in resected tissues for rapid pathological examination.…”

Section: Introductionmentioning

confidence: 99%

Methylene Blue–Based Near-Infrared Fluorescence Imaging for Breast Cancer Visualization in Resected Human Tissues

Zhang

Jiang

Huang

et al. 2019

Technol Cancer Res Treat

View full text Add to dashboard Cite

Breast-conserving surgery is facing the challenge of objective tumor margin identification intraoperatively. Near-infrared fluorescence imaging would be an ideal approach to visualize tumor margins during surgeries. In this preliminary study, the feasibility of methylene blue–based near-infrared fluorescence imaging technique for breast cancer detection was assessed in resected human breast specimens after breast cancer surgeries. Thirty patients with breast cancer scheduled for surgical treatment were enrolled, including 10 patients with preoperative chemotherapy and 20 patients without. Each of them received an injection of 1 mg/kg methylene blue intravenously 3 hours before the surgery. Then, a home-developed methylene blue–specific near-infrared fluorescence imaging system was employed to image the resected breast tissues and identify the tumor by the fluorescence contrast. Specimens were taken for pathological examinations as the reference. There were no severe adverse events attributable to methylene blue. Of 20 patients, who did not receive preoperative chemotherapy, 16 exhibited fluorescent contrast on their resected tissues (signal-to-background ratio: 1.94 ± 0.71). In contrast, tumors were identified in 3 of 10 specimens from patients who underwent preoperative chemotherapy (signal-to-background ratio: 1.63 ± 0.38). A total of 35 tissues were sampled from 30 specimens. Besides 30 tumor samples, 5 more suspicious samples with fluorescence signal were confirmed to be benign hemorrhagic tissues. Therefore, a sensitivity of 0.63 and a positive predictive value of 0.79 were achieved by the methylene blue fluorescence imaging strategy. Here, we demonstrate the feasibility of using methylene blue fluorescence imaging to identify breast cancer. Preoperative chemotherapy had an impact on imaging effect, which may reduce the detection rate. After all, methylene blue fluorescence imaging has great potential to be used into breast-conserving surgery for tumor-positive margins detection, but further clinical trial study is needed (http://www.chictr.org.cn/ Clinical Trial Registry ID: ChiCTR1800015400, Near-infrared fluorescence imaging applied in breast cancer identification with methylene blue).

show abstract

Section: Introductionmentioning

confidence: 99%

Methylene Blue–Based Near-Infrared Fluorescence Imaging for Breast Cancer Visualization in Resected Human Tissues

Zhang

Jiang

Huang

et al. 2019

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…These results are in discordance with studies recently published including a recent metaanalysis that found improved LR rates with neo-RT and adj-RT. 8,9 The heterogeneity in histologic subtypes, tumor grade, and resection status constitute well known potential sources for variability in the responses to radiotherapy. The baseline characteristics of our group are similar to the published reports in the literature, with more than 60% negative margin resections, 63% high-grade tumors, tumors with median maximum diameter of 14 cm, while more than one-third exhibited histologic evidence of invasion or adherence to adjacent organ.…”

Section: Discussionmentioning

confidence: 99%

Role of radiation therapy for retroperitoneal sarcomas: An eight‐institution study from the US Sarcoma Collaborative

Chouliaras

Senehi

Ethun

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background: The use of radiation therapy in the treatment of retroperitoneal sarcomas has increased in recent years. Its impact on survival and recurrence is unclear. Methods: A retrospective propensity score matched (PSM) analysis of patients with primary retroperitoneal soft tissue sarcomas, who underwent resection from 2000 to 2016 at eight institutions of the US Sarcoma Collaborative, was performed. Patients with metastatic disease, desmoid tumors, and palliative resections were excluded. Results: Total 425 patients were included, 56 in the neoadjuvant radiation group (neo-RT), 75 in the adjuvant radiation group (adj-RT), and 294 in the no radiotherapy group (no-RT). Median age was 59.5 years, 186 (43.8%) were male with a median follow up of 31.4 months. R0 and R1 resection was achieved in 253 (61.1%) and 143 (34.5%), respectively. Overall 1:1 match of 46 adj-RT and 59 neo-RT patients was performed using histology, sex, age, race, functional status, tumor size, grade, resection status, and chemotherapy. Unadjusted recurrence-free survival (RFS) was 35.9 months (no-RT) vs 33.5 months (neo-RT) and 27.2 months (adj-RT), P = .43 and P = .84, respectively. In the PSM, RFS was 17.6 months (no-RT) vs 33.9 months (neo-RT), P = .28 and 19 months (no-RT) vs 27.2 months (adj-RT), P = .1. Conclusions: Use of radiotherapy, both in adjuvent or neoadjuvent setting, was not associated with improved survival or reduced recurrence rate.

show abstract

Celebrating the Annals of Surgical Oncology’s 25-Year Anniversary: One of the Most Cited Surgical Journals in the World

Cited by 2 publications

References 7 publications

Methylene Blue–Based Near-Infrared Fluorescence Imaging for Breast Cancer Visualization in Resected Human Tissues

Methylene Blue–Based Near-Infrared Fluorescence Imaging for Breast Cancer Visualization in Resected Human Tissues

Role of radiation therapy for retroperitoneal sarcomas: An eight‐institution study from the US Sarcoma Collaborative

Contact Info

Product

Resources

About